<DOC>
	<DOC>NCT03043053</DOC>
	<brief_summary>This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin in obese adults, ages 18-45 years old. Subjects will be randomized to receive of intranasal oxytocin or placebo (3 sprays per nostril, 4 times per day) for 8 weeks. Study visits include screening to determine eligibility, a 2-part baseline visit, and visits every 2 weeks thereafter until week 14, with a safety follow-up visit 6 weeks after the last dose of study drug. Study procedures include behavioral, metabolic, neuroimaging, and endocrine assessments.</brief_summary>
	<brief_title>The Effects of Oxytocin in Obese Adults</brief_title>
	<detailed_description />
	<mesh_term>Oxytocin</mesh_term>
	<criteria>1845 years old; BMI 3045 kg/m2 Use of drug affecting metabolism, glucose, or appetite; history of medication changes within 4 weeks of enrollment; active substance use; history of cardiovascular disease, gastrointestinal disorders, bariatric surgery, epilepsy, untreated thyroid disease; hematocrit &gt;2% below normal; fasting glucose &gt; 125 mg/dL; ALT or AST &gt;2.5 times upper limit of normal; Cr &gt;1.5 mg/dL; hyponatremia; pregnancy or breastfeeding; unwilling to use medically acceptable form of contraception (females only)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>weight loss</keyword>
	<keyword>body mass index</keyword>
	<keyword>oxytocin</keyword>
	<keyword>magnetic resonance imaging</keyword>
</DOC>